Meda acquires remaining Xerese rights in North America
In February 2010, Meda in-licensed exclusive North American rights to Xerese – a patented product for treatment of cold sores (herpes labialis). Under that agreement, Meda pays the collaboration partner Medivir AB mid-teens and minimum royalties on net sales. Today, Meda has acquired all rights for Xerese in North America and the royalties have been reduced to zero. The purchase price was 45 MUSD. Under the terms of the new agreement, Meda will seek to develop new products for which Medivir will receive mid-single digit royalties on net sales and a milestone payment of 10 MUSD on approval